Research institutes‌ Clause Samples

Research institutes‌. Universidad Politécnica de Madrid CSIC (Spanish Research Council) Instituto Tecnológico Agrario de Castilla y ▇▇▇▇ (ITACyL) Institut de la Recerca y Tecnologia Agroalimentaries IRTA Instituto Valenciano de Investigación Agraria IVIA [List here if needed the names, addresses, contact person names and details of the Utilisation Agencies] GENOPLANTE-VALOR ▇▇▇, ▇▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇▇▇▇ 91034 Evry France Contact person: ▇▇▇▇▇▇ ▇▇▇▇▇▇ Tel: +▇▇ (▇)▇ ▇▇ ▇▇ ▇▇ 00 Email: ▇▇▇▇▇▇@▇▇▇▇▇▇▇▇▇▇.▇▇▇ GVS GmbH / Head of PIA (Plant Innovation Agency) ▇▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇-▇▇ D-53115 Bonn Germany Contact person: ▇▇▇▇▇ ▇▇▇▇▇▇ Tel: +▇▇ (▇) ▇▇▇▇▇▇▇▇▇▇ Email: ▇▇▇▇▇▇▇@▇▇▇-▇▇▇▇▇▇.▇▇ INVEGEN Asociación para el Fomento de la I+D Tecnológica en Genómica Vegetal C/▇▇▇▇▇▇▇ 27 8º G. 28001 Madrid Spain Contact Person: ▇▇▇▇▇▇▇ ▇▇▇▇ ▇▇ Gauna Tel: +▇▇ ▇▇▇ ▇▇ ▇▇ ▇▇ Email: ▇▇▇▇▇▇▇▇▇▇@▇▇▇▇▇▇▇.▇▇▇ FCT: Fundação para a Ciência e a Tecnologia Av. ▇. ▇▇▇▇▇▇ ▇, 126 1249- 074 Lisboa Portugal Contact person: ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ Tel: +▇▇▇ ▇▇ ▇▇▇▇▇▇▇ Email: ▇▇▇▇▇▇▇▇.▇▇▇▇▇▇▇@▇▇▇.▇▇▇▇▇.▇▇ [List here if needed the names, addresses, contact person names and details of the Affiliates] [Insert here, if Spanish Participants are involved, the signed letter by which INVEGEN engages to comply with the terms of the present Consortium Agreement] INVEGEN S. A. (hereinafter referred to as “INVEGEN”) Asociación para el Fomento de la I+D Tecnológica en Genómica Vegetal C/▇▇▇▇▇▇▇ 27 8º G. 28001 Madrid Spain Represented by: ▇▇▇▇▇▇▇ ▇▇▇▇ ▇▇ Gauna Tel: +▇▇ ▇▇ ▇▇▇▇▇▇▇ Email: ▇▇▇▇▇▇▇▇▇▇@▇▇▇▇▇▇▇.▇▇▇ - knowing the Consortium Agreement (“CA”) with options for Collaborative Research Projects of 2009 Call of the PLANT-KBBE Initiative and its whole contents including its annexes - hereby acknowledges and ensures that,
View Source
Research institutes‌. The OeAW is continuing its knowledge-oriented scientific commitment, combined with its claim to excellence, in its 26 research institutes (as of January 1, 2024) in this PA period. The research institutes, with their broad range of disciplines, see themselves as innovative drivers within the Austrian and European research landscape, in close cooperation with university partners, be it in the joint recruitment of scientific leaders, in the postgraduate promotion of young researchers, in particular through joint doctoral programs, or in the joint procurement and use of state-of-the-art research infrastructure. The OeAW's research activities are continuously subject to quality assurance in line with international standards and in accordance with its scientific mission. The Academy has many years of experience with scientific evaluation processes; the OeAW Research Board, which is made up of prestigious scientists including Nobel Prize winners, assists in the independent selection of scientific evaluators and in the preparation of important decisions on scientific issues. In regular intervals – full evaluations generally every five years – with the exclusive participation of independently selected, impartial, internationally renowned scientists from abroad, the scientific achievements of each institute are evaluated, recommendations for the further development of the institute are drawn up, and the basis for decisions by management bodies is laid. Evaluation is based on standardized criteria in the areas of publication output (including excellence-oriented, bibliometric analysis, if applicable), acquisition of third- party funding (third party share, acquisition of high-ranking grants such as ERC, etc.), and promotion of young researchers (proportion of excellent young researchers, academic theses). Highly cited monographs or publications in the best journals and the acquisition of prestigious grants are expected from each individual research group or similar. In addition, and this is essential, there is the direct qualitative determination of the strengths and weaknesses or future potential of the individual research groups. These are analyzed by the evaluation team in the course of an on-site visit lasting several days, including discussions with researchers working at the institute at all career levels, with administrative staff and also with members of the Presiding Committee. In addition to evaluations, excellence-oriented tendering and appointment proced...
View Source

Related to Research institutes‌

  • Research Independence The Company acknowledges that each Underwriter’s research analysts and research departments, if any, are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriter’s research analysts may hold and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of its investment bankers. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against such Underwriter with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriter’s investment banking divisions. The Company acknowledges that the Representative is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short position in debt or equity securities of the Company.

  • Technology Research Analyst Job# 1810 General Characteristics

  • Orally Administered Anticancer Medication In accordance with RIGL § 27-20-67, prescription drug coverage for orally administered anticancer medications is provided at a level no less favorable than coverage for intravenously administered or injected cancer medications covered under your medical benefit.

  • Principal Investigator The Research Project will be supervised by _____________ (Principal Investigator). If for any reason this individual is unable to continue to serve as principal investigator and a successor acceptable to both the University and the Sponsor is not available, this Agreement shall be terminated as provided in Article 6.

  • Research Funding (a) During each Collaboration Term and in connection with any wind-down activities contemplated by Section 13.4. Gilead shall reimburse Hookipa for all Out-of-Pocket Costs actually incurred (with no markup) by Hookipa in connection with the applicable Program, to the extent specifically contemplated in the applicable Research Plan and in accordance with the applicable Research Budget. Gilead shall reimburse the undisputed amount of such Out-of-Pocket Costs incurred in a [***] within [***] days after receipt from Hookipa of an invoice therefor issued within [***] days after the end of such [***]. (b) During each Collaboration Term for a Program, Gilead shall reimburse Hookipa at the FTE Rate for the costs of any FTEs (not to exceed the number of FTEs specified in the applicable Research Plan for such Program for any period without first obtaining, in each case, Gilead’s prior written consent) actually performing activities allocated to Hookipa under such Research Plan. Hookipa shall provide to Gilead, within [***] days after the end of each [***] during each Collaboration Term, a report indicating the number of FTEs actually provided by Hookipa with respect to each Program during such [***], Hookipa shall use standard industry systems and processes to record the number of hours and FTEs actually applied to each Program, which systems and processes shall be consistently and equitably applied to all Hookipa research programs with Third Parties. Gilead shall reimburse Hookipa the undisputed amount for such FTE costs incurred in a [***] within [***] days after receipt from Hookipa of an invoice therefor issued within [***] days after the end of each [***]. (c) For clarity, Gilead shall not be obligated to reimburse Hookipa for any costs or expenses incurred by Hookipa in the course of its activities under the Programs, other than: (i) those costs and expenses expressly identified in this Section 9.6 or elsewhere in this Agreement; (ii) reimbursement for the supply of Licensed Products to Gilead in accordance with the terms of any supply agreement entered into by the Parties pursuant to Section 7.2; or (iii) any other costs and expenses approved by Gilead in writing in advance.